Ultrasound contrast developer Sonus Pharmaceuticals of Bothell,WA, has extended its relationship with Abbott Laboratories toinclude the clinical development and marketing of Sonus' EchoGenagent in the U.S.Last week's deal builds on a relationship between
Ultrasound contrast developer Sonus Pharmaceuticals of Bothell,WA, has extended its relationship with Abbott Laboratories toinclude the clinical development and marketing of Sonus' EchoGenagent in the U.S.
Last week's deal builds on a relationship between Sonus and Abbottthat began in 1993 for manufacturing of EchoGen. Under the newagreement, Abbott will pay Sonus $31 million in up-front, clinicalsupport, and milestone payments in return for U.S. marketing rights.In addition, Abbott paid $4 million for warrants to acquire 500,000shares of Sonus stock, equal to about 6% of shares outstanding.Sonus will receive 47% of net EchoGen revenues in the U.S. andthe company retains some co-promotion rights to EchoGen in theU.S.
EchoGen has completed phase III radiology and cardiology trialsin the U.S. and Sonus expects to file a new drug application forthe agent this year, followed by a filing with the European MedicinesEvaluation Agency. French contrast firm Guerbet has rights toEchoGen in Europe, while Daiichi Pharmaceutical retains marketingrights for the product in the Pacific Rim.
What a New PSMA PET/CT Study Reveals About Local PCa Treatment and High-Risk Recurrence
May 16th 2025For patients at high-risk for biochemical recurrence of prostate cancer, PSMA PET/CT findings revealed that 77 percent had one or more prostate lesions after undergoing local radiation therapy or radical prostatectomy, according to a recent study.
Can Emerging AI Software Offer Detection of CAD on CCTA on Par with Radiologists?
May 14th 2025In a study involving over 1,000 patients who had coronary computed tomography angiography (CCTA) exams, AI software demonstrated a 90 percent AUC for assessments of cases > CAD-RADS 3 and 4A and had a 98 percent NPV for obstructive coronary artery disease.